上海张江（集团）有限公司（前身上海市张江高科技园区开发公司）成立于1992年7月28日，坚持“科学城开发主力军、新兴产业推动者、科创生态营造者”的战略定位，承担建设上海科创中心核心承载区、国际一流科学城的重要使命，统筹张江科学城开发建设、项目引进、产业培育、功能服务、创新创业氛围营造等重要功能。未来，将持续聚焦科创策源，做强产业服务，做优产城融合，注重高质量发展，加快成为卓越的创新策源和产业发展生态综合服务商，持续打造引领区更高水平科创生态。
Zhangjiang Group (formerly known as Shanghai Zhangjiang InnoPark Development Company) was established on July 28, 1992. As an engine for the development of Zhangjiang Science City, a booster for emerging industries, and a creator of a science and innovation ecosystem, the Group shoulders the responsibility of developing Zhangjiang Science City, attracting investment projects, cultivating new industries, providing services, and creating a favorable environment for innovation and start-ups. In the future, the Group will continue to focus on the source of science and technology innovation, better industrial services, integration of work and life, and high-quality development, and accelerate to become an outstanding provider of comprehensive ecological services for innovation and industrial development and create a higher-level science and technology innovation ecology in Pudong New Area.

The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members.
The diverse membership base covers many of the world’s top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world.
https://bayhelix.org/

eChinaHealth is a new business of eChinaChem in the field of medical health which is China's leading pharmaceutical and chemical B2B company. In 2019, eChinaHealth and the American Society of Clinical Oncology (ASCO) signed the exclusive agency rights for ASCO official journals and magazines in Greater China, including the Journal of Clinical Oncology (JCO), Academic and business journals such as Journal of Oncology Practice (JOP), The ASCO Post (The ASCO Post), and more.
The ASCO Global Conference Abstracts and Data are the sole responsibility and operation by the Doctor Evidence (DRE) platform of the physician evidence company. eChinaHealth also signed the exclusive China agent for the DRE platform. Oncologists can use this AI-enabled platform to conduct in-depth queries on ASCO and other medical literature data, including advanced terminology search, concept identification, author analysis, and timeline analysis of authors' associations with other published literature. Advanced search capabilities allow users to search for comparisons and analyses across all calendar summaries, and present results and trends. The DRE platform includes summaries and data of all ASCO conferences over the past 20 years, enabling R & D personnel to track R & D trends and conduct longitudinal analysis and investigation of evolving data.
http://www.echinahealth.com/

CBA is an independent, non-political, not-for-profit professional organization led by its board of directors and executive committees. Currently, CBA has over 3000 registered individual members. Most of its members are from universities, research institutions, biopharmaceutical companies, law firms, venture capital firms, and government agencies. Over 80 percent of the CBA members have doctoral degrees.
CBA has grown to be a truly international organization, with members residing in the U.S., China, Europe, Canada, Singapore, Japan, Australia, and other countries and regions. CBA’s mission is to promote career advancement and collaboration among Chinese-American biopharmaceutical professionals, and to promote technology transfer and entrepreneurship, especially between the U.S. and China, as well as countries and regions in the Pacific Rim. Since its inception in 1995, CBA has been playing a prominent role in the Chinese and U.S. biopharmaceutical industries. Every year, CBA organizes a number of specially designed workshops, seminars, meetings, and networking events in both China and the U.S. To learn more about CBA, please visit
www.cba-usa.org.

Sino-American Pharmaceutical Professionals Association - Greater Philadelphia (SAPA-GP) is a non-profit (501(c)(3)) professional organization founded in 2002 (www.sapa-gp.org). We strive to serve the rapidly growing pharmaceutical professional community in the Greater Philadelphia area. The Greater Philadelphia area is one of the major hubs for global pharmaceutical companies (e.g. BMS, GSK, Johnson & Johnson, Merck, Pfizer, Teva), biotech companies (e.g. Alliance Pharma, Frontage Laboratories, PuraCap, Shire) and academic institutions (e.g. University of Pennsylvania, Thomas Jefferson University, Temple University, Drexel University, Rowan University, Villanova University). Over past decades, SAPA-GP has established a broad member base and become the premier organization in the region for bridging the pharmaceutical and healthcare industries of China and the US.
Our Missions
• To promote pharmaceutical sciences and biotechnology
• To contribute to public health education by raising public awareness
• To facilitate scientific and business cooperation between US and China
• To foster career development of pharmaceutical professionals
Our members consist of
• Scientists, clinicians, and executives from pharmaceutical and biotech companies
• Students and postdoctoral fellows from academic institutions and universities
• Business and thought leaders from financial institutions and healthcare industries
Our Events
• Annual conference
• Scientific symposiums and webinars
• Business development workshops
• Career development workshops & Job fairs
• Professional training
www.cba-usa.org.

AAIH is a not-for-profit (501(c)(4)) founded in 2018 and formally launching in January 2019 (https://theaaih.org/). We are a global advocacy organization for the advancement and use of AI/ Machine Learning in healthcare to improve patients’ lives and create more efficient, sustainable, and accessible healthcare systems. Through investment, invention, and innovation in AI, the AAIH and our member organizations are creating novel interventions and product solutions that reduce failure rates and costs while improving quality across the entire healthcare spectrum. AAIH is a diverse member base that includes dedicated healthcare AI companies and organizations, as well as, those utilizing AI platforms for biomedical discovery, clinical research, diagnostics and devices, and precision medicine.
https://theaaih.org/